Last reviewed · How we verify
Pf-07248144 (pf-07248144)
PF-07248144 is an investigational drug developed by Pfizer Inc. It is currently in the clinical trial phase and has not yet received FDA approval. The drug is being evaluated for its potential in treating various conditions, but specific details about its mechanism of action, safety profile, and commercial prospects are limited due to its developmental stage. Early clinical trials have provided some insights into its efficacy and safety, but more data is needed before it can be fully characterized. The drug's development timeline and regulatory milestones are ongoing, and Pfizer continues to conduct studies to determine its full therapeutic potential.
At a glance
| Generic name | pf-07248144 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Small molecule inhibitor |
| Target | Specific protein involved in disease pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | Not available |
Approved indications
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
Pipeline indications
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP3A4 substrates
Key clinical trials
- A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine) (PHASE1)
- A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults (PHASE1)
- Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. (PHASE2)
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (PHASE3)
- A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults (PHASE1)
- A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144 (PHASE1)
- Study of PF-07248144 in Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-07248144 CI brief — competitive landscape report
- Pf-07248144 updates RSS · CI watch RSS
- Pfizer portfolio CI